Homocysteine and Cardiovascular Disease
Helga Refsum, Per Magne Ueland, Ottar Kjell Nygard
Annual Review of Medicine · 1998 · 2,180 citations
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Refsum, H., Ueland, P. M., Nygard, O. K., & Vollset, S. E. (1998). Homocysteine and cardiovascular disease. Annual Review of Medicine, 49(1), 31–62. https://doi.org/10.1146/annurev.med.49.1.31
In text: (Refsum et al., 1998)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
An elevated level of total homocysteine (tHcy) in blood, denoted hyperhomocysteinemia, is emerging as a prevalent and strong risk factor for atherosclerotic vascular disease in the coronary, cerebral, and peripheral vessels, and for arterial and venous thromboembolism. The basis for these conclusions is data from about 80 clinical and epidemiological studies including more than 10,000 patients. Elevated tHcy confers a graded risk with no threshold, is independent of but may enhance the effect of the conventional risk factors, and seems to be a particularly strong predictor of cardiovascular mortality. Hyperhomocysteinemia is attributed to commonly occurring genetic and acquired factors including deficiencies of folate and vitamin B12. Supplementation with B-vitamins, in particular with folic acid, is an efficient, safe, and inexpensive means to reduce an elevated tHcy level. Studies are now in progress to establish whether such therapy will reduce cardiovascular risk.
Related papers
- A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease1995
- Tietz Textbook of Clinical Chemistry1999
- Hyperhomocysteinemia: An Independent Risk Factor for Vascular Disease1991
- Homocysteine and Risk of Ischemic Heart Disease and Stroke2002
- Homocysteine and Atherothrombosis1998
Metadata from OpenAlex (CC0). Citations are generated from the published record.